CMS Finalizes Favorable Reimbursement for Carlsmed's aprevo® Lumbar Procedures
CARL sits 48% above its 52-week low of $8.5.
Summary
CMS has finalized a favorable inpatient reimbursement policy for Carlsmed's aprevo® Lumbar spinal fusion procedures, creating three new MS-DRGs (523-525) effective October 1, 2026. This reassignment moves aprevo® cases into higher-paying DRG categories, directly improving hospital economics and likely accelerating adoption. The decision follows Carlsmed's strong Q1 2026 results, where revenue grew 58% to $16.1M, and adds a significant regulatory tailwind. With a $342M market cap, this reimbursement clarity removes a key commercial barrier and could meaningfully expand the addressable market. The policy takes effect in two months, giving hospitals time to plan for the new codes. The new fragment confirms the announcement and specifies the favorable reimbursement applies to FY2027.
At the time of this announcement, CARL was trading at $12.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $342.3M. The 52-week trading range was $8.50 to $17.19. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.